|本期目录/Table of Contents|

[1]李晞,时丽,姚尚武,等.帕利哌酮缓释片联合奥氮平对精神分裂症患者血清脑源性神经营养因子和神经生长因子水平及对代谢综合征影响[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):368-371.[doi:10.3969/j.issn.1672-271X.2021.04.007]
　LI Xi,SHI Li,YAO Shang-wu,et al.Analysis of the effect of pallidone sustained release tablets combined with olanzapine on serum BDNF, NGF levels and metabolic syndrome in schizophrenics[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(04):368-371.[doi:10.3969/j.issn.1672-271X.2021.04.007]
点击复制

帕利哌酮缓释片联合奥氮平对精神分裂症患者血清脑源性神经营养因子和神经生长因子水平及对代谢综合征影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年04期
页码:
368-371
栏目:
临床研究
出版日期:
2021-08-10

文章信息/Info

Title:
Analysis of the effect of pallidone sustained release tablets combined with olanzapine on serum BDNF, NGF levels and metabolic syndrome in schizophrenics
作者:
李晞; 时丽; 姚尚武; 陈大春
作者单位：100096北京，北京回龙观医院检验科（李晞、时丽、姚尚武），精神科（陈大春）
Author(s):
LI Xi1;  SHI Li1;  YAO Shang-wu1;  CHEN Da-chun2
(1.Department of Laboratory Medicine, 2.Department of Psychiatry, Beijing Huilongguan Hospital, Beijing 100096， China)
关键词:
帕利哌酮缓释片; 奥氮平; 精神分裂症; 代谢综合征; 脑源性神经营养因子; 神经生长因子
Keywords:
sustained release tablets of pariprasidone;  olanzapine;  schizophrenia;  metabolic syndrome;  brain-derived neurotrophic factor;  nerve growth factor
分类号:
R749.3R589
DOI:
10.3969/j.issn.1672-271X.2021.04.007
文献标志码:
A
摘要:
目的探讨帕利哌酮缓释片联合奥氮平对精神分裂症患者血清脑源性神经营养因子（BDNF）、神经生长因子（NGF）及对代谢综合征（MS）影响。方法选择2017年5月至2019年5月期间北京回龙观医院收治的精神分裂症患者83例，依据随机表法分为联合组42例与对照组41例。对照组患者给予奥氮平治疗，联合组在对照组基础上结合帕利哌酮缓释片治疗。2组疗程均为8周。比较2组治疗疗效，治疗前后阳性和阴性症状量表（PANSS）评分、BDNF、NGF水平变化及MS发生情况。结果联合组精神分裂症患者治疗8周总有效率（90.48%）高于对照组（70.73%，P<0.05）。联合组精神分裂症患者治疗8周PANSS总分[（38.72±3.61）分]低于对照组[（45.93±4.25）分，P<0.05]。联合组精神分裂症患者治疗8周血清BDNF[（3.61±0.18）ng/mL]和NGF[（42.31±2.08）pg/mL]高于对照组[（3.09±0.23）ng/mL、（38.03±2.24）pg/mL，P<0.05]。联合组精神分裂症患者MS发生率（28.57%）低于对照组（51.22%，P<0.05）。结论帕利哌酮缓释片联合奥氮平对精神分裂症患者效果良好，其原因可能与上调BDNF、NGF水平相关，可降低MS发生率。
Abstract:
ObjectiveTo investigate the effect of sustained-release tablets of parlipidone combined with olanzapine on the levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and metabolic syndrome (MS) in patients with schizophrenia.Methods83 schizophrenics admitted to our hospital from May 2017 to may 2019 were randomly divided into a combined group (42 cases) and control group (41 cases). The patients in the control group were treated with olanzapine, while the patients in the combined group were treated with palipexone sustained-release tablets on the basis of the control group. The course of treatment in both groups was 8 weeks. The therapeutic effect, PANSS score, BDNF, NGF levels before and after treatment were comparable between the two groups.ResultsThe combined group effective (90.48%) was higher control group (70.73%, P<0.05). After treatment of 8 weeks, the combined group PANSS total score (38.72±3.61) was lower control group (45.93±4.25, P<0.05). After treatment of 8 weeks, the combined group serum BDNF (3.61±0.18)ng/mL and NGF (42.31±2.08)pg/mL were higher controlgroup (3.09±0.23)ng/mL and (38.03±2.24)pg/mL (P<0.05). The combined group incidence of MS (28.57%) was lower control group (51.22%, P<0.05).ConclusionThe effect of pallidone sustained release tablets combined with olanzapine on schizophrenia is good, it may be related to the up regulation of BDNF and NGF, can reduce the incidence of MS.

参考文献/References:

[1]张文润，鲁文慧，刘万普.河北省沧州市严重精神障碍患病情况的流行病学调查[J].中华神经医学杂志，2017，16(1):78-81.
[2]郭鑫，王静，李丽娜，等.精神分裂症与抑郁症患者认知功能障碍的比较研究[J].医学研究生学报，2016，29(12):1255-1259.
[3]白凤凤，杨建立，李涛，等.精神分裂症伴发代谢综合征患者的认知功能特点[J].中国慢性病预防与控制，2016，24(12):918-920.
[4]朱桂东，宋清海，徐伟杰，等.齐拉西酮联合奥氮平对老年难治性精神分裂症患者症状及血清瘦素和脑源性神经营养因子水平的影响[J].中国慢性病预防与控制，2019，27(3):219-222.
[5]张鸿燕,郝晓楠,王雪芹,等.帕利哌酮缓释片治疗非急性期精神分裂症疗效及安全性的开放性研究[J].中华精神科杂志,2012,45(1):20-24.
[6]辛一帆，李光梅，郑兴华.精神分裂症患者社会支持程度与血清神经功能指标水平及阴性症状、抑郁症状的相关性[J].神经疾病与精神卫生，2019，19(4):371-376.
[7]世界卫生组织.ICD精神与行为障碍分类临床描述与诊断要点[M].范肖东，汪向东，于欣，等，译.北京:人民卫生出版社，1993:72-79.
[8]Wu Y, Kang R, Yan Y，et al. Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015[J]. J Int Med Res，2018，46(10):4039-4049.
[9]陈琪，施辉，戴立彬，等.氯氮平和齐拉西酮对精神分裂症患者体质量、血浆神经肽Y及瘦素影响的研究[J].东南国防医药，2016，18(2):142-144，150.
[10]张云飞，马长林，彭晓晔.奥氮平与利培酮在精神分裂症治疗中疗效差异分析[J].临床药物治疗杂志，2018，16(12):34-37.
[11]李涛，李界兴，尚同军，等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志，2019，48(5):657-660.
[12]刘曼，胡杨，万姝.奥氮平与喹硫平联合治疗对精神分裂症的疗效观察[J].西南国防医药，2019，29(5):538-540.
[13]王群芬.帕利哌酮缓释片治疗精神分裂症的临床效果及安全性[J].中国基层医药，2018，25(5):566-569.
[14]王金成，王朝敏，葛怡然，等.帕利哌酮缓释片治疗精神分裂症的临床研究[J].中国临床药理学杂志，2018，34(7):786-789.
[15]于筝，秦英杰.氨磺必利联合帕利哌酮缓释片治疗精神分裂症的效果分析[J].医学综述，2018，24(17):3516-3519，3524.
[16]万齐根，占瑾琼，杨远坚，等.阿立哌唑对精神分裂症患者临床症状及血清神经营养因子水平的影响[J].中国神经精神疾病杂志，2018，44(4):217-221.
[17]李泽兵，李冬，林萍，等.精神分裂症住院患者血清细胞因子和神经营养因子水平的辅助诊断价值[J].国际检验医学杂志，2017，38(6):725-728.
[18]蒋光芬，王任昌，刘颖.奥氮平对伴或不伴代谢综合征的精神分裂症病人认知功能的差异性影响分析[J].蚌埠医学院学报，2019，44(8):1027-1029.

相似文献/References:

[1]朱羞阳,佟洋,李驰荣,等.选择性5-羟色胺再摄取抑制剂与奥氮平联合治疗难治性抑郁症的临床疗效[J].医学研究与战创伤救治(原医学研究生学报),2013,15(02):125.
　Air force Hangzhou Aviation Medicine Assessment and Training Center,Hangzhou,Zhejiang 00,et al.ZHU Xiu-yang,TONG Yang,LI Chi-rong[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):125.
[2]林小燕,邱 静,王 锐,等.奥氮平、喹硫平对阿尔茨海默病患者睡眠呼吸的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):8.[doi:10.3969/j.issn.1672-271X.2015.01.003]
　LIN Xiao-yan,QIU Jing,WANG Rui,et al.Effects of olanzapine and quetiapine on sleep-breathing in patients with Alzheimer disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):8.[doi:10.3969/j.issn.1672-271X.2015.01.003]
[3]汪勇,赵武伟,汪朝晖,等.小剂量奥氮平与奋乃静治疗肝移植术后精神障碍的对照研究[J].医学研究与战创伤救治(原医学研究生学报),2016,18(06):572.[doi:10.3969/j.issn.1672-271X.2016.06.004]
　WANG Yong,ZHAO Wu-wei,WANG Zhao-hui,et al.Treatment of patients with mental disorders after liver transplantation by using olanzapine or perphenazine: a control study[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(04):572.[doi:10.3969/j.issn.1672-271X.2016.06.004]
[4]王国平,李霞,何朗,等.奥氮平联合盐酸吗啡缓释片治疗癌性疼痛的疗效和安全性分析[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):622.[doi:10.3969/j.issn.1672-271X.2020.06.014]
　WANG Guo-ping,LI Xia,HE Lang,et al.Effect and safety analysis of olanzapine combined with morphine hydrochloride sustained release tablets in the treatment of cancerous pain[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(04):622.[doi:10.3969/j.issn.1672-271X.2020.06.014]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-08-10